Home News Insights Trading halts Paper trading Guide Community My account

Market calendarChecking market schedule

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Copyright © WAPE. All rights reserved.

Loading news article.

Evommune to Present Phase 2a Data for EVO301 | WAPE

FilingSEC EDGAR8-K

Evommune to Present Phase 2a Data for EVO301

Sep 23, 2026, 16:05 ET · SEC accepted

StagePhase 2a

Filing content

The company will present Phase 2a data for its atopic dermatitis candidate EVO301 at the upcoming EADV Congress.

AI summary of the filing. Please also check the source.

Related companies

Evommune, Inc.EVMNView stock

Analyzed by WAPE AI.

Preparing English content…

Comments —

Comment

Loading comments…